EOC Pharma’s License and Collaboration Agreement for ABI-009

Sidley Austin LLP advised EOC Pharma on the deal.

EOC Pharma entered into an exclusive license agreement with Aadi Bioscience (Aadi) for the development and commercialization of ABI-009 (FYARRO) in Greater China including mainland China, Hong Kong, Macau, and Taiwan.

EOC Pharma is a leading biopharmaceutical company in China, specializing in oncology. Aadi is a Los Angeles-based biopharmaceutical company focusing on precision therapies for genetically defined cancers. FYARRO (ABI-009, sirolimus albumin-bound nanoparticles) is an mTOR inhibitor complexed with human albumin.

Under the license agreement, EOC Pharma will obtain exclusive rights to develop and commercialize ABI-009 in Greater China. EOC Pharma will be responsible for development, regulatory submissions, and commercialization in the territory. Aadi Bioscience retains full worldwide rights outside of the partnered territory.

The Sidley team was led by partner Lei Li (Picture), with support from senior China advisor Ling Chen.

Involved fees earner: Lei Li – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: EOC Pharma;


Author: Michael Patrini